- Home
- CURI vs MOLN Comparison
CURI vs MOLN Comparison
Compare CURI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CURI | MOLN |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.0M | 147.5M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CURI | MOLN |
|---|---|---|
| Price | $2.88 | $3.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $5.33 | ★ $10.36 |
| AVG Volume (30 Days) | ★ 496.9K | 1.9K |
| Earning Date | 11-11-2026 | 10-29-2026 |
| Dividend Yield | ★ 12.23% | N/A |
| EPS Growth | ★ 54.17 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $78,043,000.00 | N/A |
| Revenue This Year | $10.59 | N/A |
| Revenue Next Year | $12.05 | $450.00 |
| P/E Ratio | $23.33 | ★ N/A |
| Revenue Growth | ★ 9.52 | N/A |
| 52 Week Low | $2.30 | $3.52 |
| 52 Week High | $5.10 | $5.36 |
Technical Indicators
Market Signals| Indicator | CURI | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 39.53 |
| Support Level | $2.81 | N/A |
| Resistance Level | $2.97 | $4.21 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 68.29 | 15.12 |
Price Performance
Historical ComparisonAbout CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.